Clinical trials: Advanced Prostate Carcinoma
Prostate Cancer
Study of Chitosan for Pharmacologic Manipulation of AGE Levels in Prostate Cancer Patients
This study will examine the utility of chitosan for reduction of blood or tissue levels of AGEs in patients with prostate cancer who are clinically stable on androgen-deprivation therapy.
- Trial name
- NCT03712371
- Testing
- Chitosan
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Medical University of South Carolina
Metastatic Cancer, Prostate Cancer
Paricalcitol in Treating Patients With Advanced Prostate Cancer and Bone Metastases
RATIONALE: Paricalcitol may help prostate cancer cells become more like normal cells, and to grow and spread more slowly. It may also stop the growth of tumor cells in bone.
- Trial name
- NCT00634582
- Testing
- paricalcitol, immunoenzyme technique, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Wake Forest University Health Sciences
Prostate Cancer
Effects of Triptorelin When Given Every 6-months Under the Skin to Adult Males With Cancer in the Prostate
The aim of the study is to determine if triptorelin formulated for use every 6 months (given twice during the study) is effective and safe for when given by injection under the skin for the treatment of adult males with cancer in…
- Trial name
- TriptoSwitch (NCT05458856)
- Testing
- Triptorelin embonate 22.5 mg
- Where
- 39 sites in Belgium, Czechia and 5 more
- Volunteers
- 147 people
- Sponsor
- Ipsen
Prostatic Neoplasm
Efficacy and Safety of a Triptorelin 6-month Formulation in Patients With Advanced Prostate Cancer
Efficacy and safety of a triptorelin 6-month formulation in patients with advanced prostate cancer. It was assumed that during the study treatment >90% of the patients would achieve and maintain castrate levels of serum…
- Trial name
- NCT00751790
- Testing
- triptorelin embonate (INN)
- Where
- South Africa
- Volunteers
- 120 people
- Sponsor
- Debiopharm International SA
Advanced Cancer
A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer
The reason for this study is to see if the CD73 inhibitor LY3475070 alone or in combination with pembrolizumab is safe and effective in participants with advanced cancer.
- Trial name
- NCT04148937
- Testing
- LY3475070, Pembrolizumab
- Where
- 12 sites in United States, Australia and 1 more
- Volunteers
- 52 people
- Sponsor
- Eli Lilly and Company
Prostatic Neoplasm
Study to Document Treatment Patterns and to Evaluate Leuprolide and Alternative Therapeutic Approaches to the Treatments of Advanced Prostate Cancer
Document treatment patterns and evaluate LUCRIN / LUCRIN-TRIDEPOT® (Leuprolide) and alternative therapeutic approaches to the treatment of advanced prostate cancer during normal clinical practice and in accordance with the terms…
- Trial name
- NCT01081873
- Testing
- leuprolide (Lucrin/Lucrin-Tri-depot)
- Where
- 135 sites in Belgium, Luxembourg
- Volunteers
- 2,717 people
- Sponsor
- Abbott
Non-small Cell Lung Cancer, Pancreatic Cancer
Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia
Study to compare the effects of the investigational new drug (PF-06946860) and a placebo on appetite and to find out how participants with advanced cancer and anorexia feel after receiving repeated subcutaneous (SC-injected under…
- Conditions
- Non-small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, Prostate Cancer
- Trial name
- NCT04803305
- Testing
- PF-06946860
- Where
- 33 sites in United States, Canada
- Volunteers
- 18 people
- Sponsor
- Pfizer
Metastatic Cancer, Prostate Cancer
S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy
RATIONALE: Drugs used in chemotherapy, such as docetaxel, prednisone, and atrasentan work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00134056
- Testing
- atrasentan hydrochloride, docetaxel, prednisone
- Where
- 554 sites in United States
- Volunteers
- 1,038 people
- Sponsor
- SWOG Cancer Research Network
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma
11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression
This phase I trial studies if positron emission tomography (PET) imaging using 11C-YJH08 can be useful for detecting certain cell receptor expression in tumor cells in patients with cancer that has spread to other parts of the…
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
- Trial name
- NCT04927663
- Testing
- Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Rahul Aggarwal
NUT Midline Carcinoma, Triple Negative Breast Cancer
A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)
Open-label, phase I, non-randomized, multicentric study of single-agent birabresib (MK-8628) (formerly known as OTX015) administered according to two distinct regimens to participants with selected advanced tumors.
- Conditions
- NUT Midline Carcinoma, Triple Negative Breast Cancer, Non-small Cell Lung Cancer With Rearranged ALK Gene/Fusion Protein or KRAS Mutation, Castrate-resistant Prostate Cancer
- Trial name
- NCT02259114
- Testing
- Birabresib
- Volunteers
- 47 people
- Sponsor
- Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Prostate Cancer
Samarium-153 With Neoadjuvant Hormonal and Radiation Therapy for Locally Advanced Prostate Cancer
The purpose of this study is to determine the safety and effectiveness of Samarium-153 when given in combination with hormonal and external beam radiation therapy in men with high risk prostate cancer.
- Trial name
- NCT00328614
- Testing
- Samarium-153, Total Androgen Suppression (TAS) with Bicalutamide, Total androgen suppression (TAS) with Goserelin Acetate
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Advanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
This phase I trial investigates the side effects of cabozantinib and nivolumab in treating patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body…
- Conditions
- Advanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma, Advanced Hepatocellular Carcinoma, Advanced Kaposi Sarcoma
- Trial name
- NCT04514484
- Testing
- Biospecimen Collection, Cabozantinib S-malate, Computed Tomography
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Prostate Cancer, Metastatic Prostate Cancer
Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate
The main aim of this study is to assess the effectiveness and safety of the 6-month formulation of triptorelin pamoate in Chinese participants with locally advanced or metastatic cancer of the prostate.
- Conditions
- Advanced Prostate Cancer, Metastatic Prostate Cancer, Locally Advanced Prostate Cancer
- Trial name
- NCT05590793
- Testing
- Triptorelin pamoate (embonate) salt
- Where
- 36 sites in China
- Volunteers
- 195 people
- Sponsor
- Ipsen
Prostate Cancer
Abemaciclib in Combination With Androgen Deprivation Therapy for Locally Advanced Prostate Cancer
This Phase II study is designed to study the clinical and radiologic response, as well as, safety and tolerability of abemaciclib in combination with androgen deprivation therapy (ADT) in patients with localized high-risk or…
- Trial name
- RAD 1805 (NCT04298983)
- Testing
- Abemaciclib 150 MG by mouth twice daily, Androgen deprivation therapy (ADT), Radiation Therapy
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Alabama at Birmingham
Colorectal Cancer, Lung Cancer
QUILT-3.038: Active Immunotherapy CEA Vaccine in Patients With Malignancies Expressing CEA
The purpose of this study is to find out what effects (good and bad) that a cancer vaccine has on you and your cancer. The cancer vaccine is called Ad5 [E1-, E2b-]-CEA(6D)or ETBX-011 and is made by Etubics.
- Conditions
- Colorectal Cancer, Lung Cancer, Breast Cancer, Prostate Cancer
- Trial name
- NCT01147965
- Testing
- Ad5 CEA Vaccine
- Where
- 2 sites in United States
- Volunteers
- 43 people
- Sponsor
- NantCell, Inc.
Prostate Cancer, Endometrial Cancer
Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer
This is a phase 1/phase 2a study of the combination of immune checkpoint inhibitor (nivolumab) in combination with the PARP inhibitor (rucaparib) for patients with metastatic castration resistant prostate cancer (mCRPC) and…
- Trial name
- NCT03572478
- Testing
- Rucaparib, Nivolumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Chicago
Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery
This phase I trial studies the side effects and best dose of PI3Kbeta inhibitor AZD8186 when given together with docetaxel in treating patients with solid tumors with PTEN or PIK3CB mutations that have spread to other places in…
- Conditions
- Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Prostate Carcinoma, Anatomic Stage III Breast Cancer AJCC v8
- Trial name
- NCT03218826
- Testing
- Docetaxel, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 8 sites in United States
- Volunteers
- 23 people
- Sponsor
- National Cancer Institute (NCI)
Prostatic Neoplasms
Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate in Subjects With Advanced Prostate Carcinoma
The study will evaluate if Leuprolide Mesylate is safe and effective in the treatment of subjects with advanced prostate carcinoma, when administered as two injections six months apart.
- Trial name
- NCT02234115
- Testing
- Leuprolide Mesylate
- Where
- 29 sites in United States, Austria and 6 more
- Volunteers
- 137 people
- Sponsor
- Foresee Pharmaceuticals Co., Ltd.
Advanced or Recurrent Solid Tumors, Breast Neoplasms
Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
This is a single-arm, open-label study to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of talazoparib in patients with advanced tumors with DNA-repair pathway deficiencies.
- Conditions
- Advanced or Recurrent Solid Tumors, Breast Neoplasms, Ovarian Cancer, Epithelial, Ewing Sarcoma
- Trial name
- NCT01286987
- Testing
- Talazoparib
- Where
- 15 sites in United States, United Kingdom
- Volunteers
- 113 people
- Sponsor
- Pfizer
Advanced Prostate Cancer, Lower Urinary Tract Symptoms
Lucrin® Depot Efficacy and Safety Monitoring Study in Patients With Advanced Prostate Cancer and Lower Urinary Tract Symptoms (LUTS)
The purpose of the study is to determine the influence of GnRH (gonadotropin releasing hormone) analogue - Lucrin Depot 11.25 mg (Lucrin Depot 3.75mg - in Ukraine) administration on intensity of lower urinary tract symptoms…
- Trial name
- LEMON (NCT01078545)
- Testing
- Leuprolide acetate Depot Susp. 11.25 mg (Poland), 3.75 mg (Ukraine)
- Where
- 143 sites in Poland, Ukraine
- Volunteers
- 729 people
- Sponsor
- Abbott